๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
agilon health, inc. (AGL)
NYSE: AGL ยท Real-Time Price ยท USD
90.24
+0.74 (0.83%)
At close: Nov 20, 2026, 4:00 PM EST
90.45
+0.21 (0.23%)
After-hours: Nov 20, 2026, 7:40 PM EST

agilon health Earnings Call Transcripts

Fiscal Year 2026

  • Status update

    The care model combines longitudinal patient data, AI-supported insights and physician-led pathways to target high-risk care. Reported results include fewer admissions and readmissions versus Medicare fee-for-service benchmarks, alongside a 4.2 consolidated Star Rating.

  • Q3 revenue reached $1.5B and Adjusted EBITDA was $64M, prompting higher FY26 guidance. Clinical initiatives, favorable H1 cost development, and ACO growth support the outlook, while Q3 cost trend remained in the low-7% range.

  • A strategic pivot to profitability has driven improved earnings, cost control, and enhanced data capabilities, with EBITDA guidance raised and strong cash reserves. Growth opportunities remain robust, supported by disciplined contracting, successful clinical programs, and operational flexibility across multiple care models.

  • Second quarter results exceeded guidance, driven by improved medical cost trends, enhanced risk adjustment, and operational execution. Full-year 2026 guidance was raised, with continued investment in AI, clinical pathways, and a disciplined approach to growth and capital allocation.

  • AGM 2026

    The meeting focused on strategic priorities, board alignment, and operational execution, with all director nominees reelected, auditor ratified, and executive compensation approved. No shareholder questions were raised, and risks were referenced per SEC filings.

  • First quarter results exceeded expectations, driven by operational discipline, improved data, and AI integration. Full-year 2026 guidance was raised, with strong clinical program expansion and continued focus on cost management and payer contracting.

  • EGM 2026

    Two proposals were presented: a reverse stock split amendment and a potential adjournment to solicit more proxies. Both proposals passed with Board support, and final vote results will be filed with the SEC.

  • A major transformation is underway, with new contracting and clinical pathway initiatives driving financial and operational improvements. Enhanced data and AI capabilities are improving disease identification and RAF score accuracy, while network management and disciplined contracting support stability and future growth.

  • Cost trends remain elevated, especially in inpatient and oncology drug spend, but disciplined contracting and operational efficiencies have improved margins and cash position. Clinical programs and data enhancements support risk adjustment and member outcomes, while constructive payer relationships and portfolio refinement are expected to drive profitability in 2026 and beyond.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021